150 related articles for article (PubMed ID: 22634606)
21. Therapeutic potential of human elafin.
Shaw L; Wiedow O
Biochem Soc Trans; 2011 Oct; 39(5):1450-4. PubMed ID: 21936832
[TBL] [Abstract][Full Text] [Related]
22. Complete 1H, 15N and 13C assignment of trappin-2 and 1H assignment of its two domains, elafin and cementoin.
Loth K; Alami SA; Habès C; Garrido S; Aucagne V; Delmas AF; Moreau T; Zani ML; Landon C
Biomol NMR Assign; 2016 Apr; 10(1):223-6. PubMed ID: 26878852
[TBL] [Abstract][Full Text] [Related]
23. Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition.
Iqbal SM; Ball TB; Levinson P; Maranan L; Jaoko W; Wachihi C; Pak BJ; Podust VN; Broliden K; Hirbod T; Kaul R; Plummer FA
AIDS; 2009 Aug; 23(13):1669-77. PubMed ID: 19553806
[TBL] [Abstract][Full Text] [Related]
24. The role of recombinant human elafin in the resistance of A549 cells against Pseudomonas aeruginosa biofilm.
Li Q; Zhou X; Nie X; Yang J
Respiration; 2010; 79(1):68-75. PubMed ID: 19420899
[TBL] [Abstract][Full Text] [Related]
25. Oxidized elafin and trappin poorly inhibit the elastolytic activity of neutrophil elastase and proteinase 3.
Nobar SM; Zani ML; Boudier C; Moreau T; Bieth JG
FEBS J; 2005 Nov; 272(22):5883-93. PubMed ID: 16279952
[TBL] [Abstract][Full Text] [Related]
26. Modulation of inflammasome pathways by bacterial and viral pathogens.
Lamkanfi M; Dixit VM
J Immunol; 2011 Jul; 187(2):597-602. PubMed ID: 21734079
[TBL] [Abstract][Full Text] [Related]
27. The potential role of interleukin-37 in infectious diseases.
Allam G; Gaber AM; Othman SI; Abdel-Moneim A
Int Rev Immunol; 2020; 39(1):3-10. PubMed ID: 31633447
[TBL] [Abstract][Full Text] [Related]
28. SLPI and elafin: one glove, many fingers.
Williams SE; Brown TI; Roghanian A; Sallenave JM
Clin Sci (Lond); 2006 Jan; 110(1):21-35. PubMed ID: 16336202
[TBL] [Abstract][Full Text] [Related]
29. Anti-HIV-1 activity of elafin is more potent than its precursor's, trappin-2, in genital epithelial cells.
Drannik AG; Nag K; Yao XD; Henrick BM; Jain S; Ball TB; Plummer FA; Wachihi C; Kimani J; Rosenthal KL
J Virol; 2012 Apr; 86(8):4599-610. PubMed ID: 22345469
[TBL] [Abstract][Full Text] [Related]
30. Localization of porcine trappin-2 (SKALP/elafin) in trachea and large intestine by in situ hybridization and immunohistochemistry.
Suzuki Y; Furukawa M; Abe J; Kashiwagi M; Hirose S
Histochem Cell Biol; 2000 Jul; 114(1):15-20. PubMed ID: 10959818
[TBL] [Abstract][Full Text] [Related]
31. Identification and sequence analysis of two new members of the SKALP/elafin and SPAI-2 gene family. Biochemical properties of the transglutaminase substrate motif and suggestions for a new nomenclature.
Zeeuwen PL; Hendriks W; de Jong WW; Schalkwijk J
J Biol Chem; 1997 Aug; 272(33):20471-8. PubMed ID: 9252357
[TBL] [Abstract][Full Text] [Related]
32. The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core.
Schalkwijk J; Wiedow O; Hirose S
Biochem J; 1999 Jun; 340 ( Pt 3)(Pt 3):569-77. PubMed ID: 10359639
[TBL] [Abstract][Full Text] [Related]
33. Chlamydia trachomatis induces anti-inflammatory effect in human macrophages by attenuation of immune mediators in Jurkat T-cells.
Azenabor AA; Cintrón-Cuevas J; Schmitt H; Bumah V
Immunobiology; 2011 Dec; 216(12):1248-55. PubMed ID: 21802168
[TBL] [Abstract][Full Text] [Related]
34. The role of platelets in defence against pathogens.
Clemetson KJ
Hamostaseologie; 2011 Nov; 31(4):264-8. PubMed ID: 21709931
[TBL] [Abstract][Full Text] [Related]
35. SLPI and elafin: multifunctional antiproteases of the WFDC family.
Scott A; Weldon S; Taggart CC
Biochem Soc Trans; 2011 Oct; 39(5):1437-40. PubMed ID: 21936829
[TBL] [Abstract][Full Text] [Related]
36. Regulation of secretory leukocyte proteinase inhibitor (SLPI) production by human bronchial epithelial cells: increase of cell-associated SLPI by neutrophil elastase.
van Wetering S; van der Linden AC; van Sterkenburg MA; Rabe KF; Schalkwijk J; Hiemstra PS
J Investig Med; 2000 Sep; 48(5):359-66. PubMed ID: 10979241
[TBL] [Abstract][Full Text] [Related]
37. Controlling pathogenic inflammation to fungi.
Romani L; Puccetti P
Expert Rev Anti Infect Ther; 2007 Dec; 5(6):1007-17. PubMed ID: 18039084
[TBL] [Abstract][Full Text] [Related]
38. Antimicrobial peptides: mediators of innate immunity as templates for the development of novel anti-infective and immune therapeutics.
Hiemstra PS; Fernie-King BA; McMichael J; Lachmann PJ; Sallenave JM
Curr Pharm Des; 2004; 10(23):2891-905. PubMed ID: 15379675
[TBL] [Abstract][Full Text] [Related]
39. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases.
Tlaskalová-Hogenová H; Stepánková R; Hudcovic T; Tucková L; Cukrowska B; Lodinová-Zádníková R; Kozáková H; Rossmann P; Bártová J; Sokol D; Funda DP; Borovská D; Reháková Z; Sinkora J; Hofman J; Drastich P; Kokesová A
Immunol Lett; 2004 May; 93(2-3):97-108. PubMed ID: 15158604
[TBL] [Abstract][Full Text] [Related]
40. Adenoviral E1A suppresses secretory leukoprotease inhibitor and elafin secretion in human alveolar epithelial cells and bronchial epithelial cells.
Higashimoto Y; Yamagata Y; Iwata T; Ishiguchi T; Okada M; Masuda M; Satoh H; Itoh H
Respiration; 2005; 72(6):629-35. PubMed ID: 16355004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
